Nanjing Well Pharmaceutical Co Ltd (603351) — Capital Reinvestment Ratio
Nanjing Well Pharmaceutical Co Ltd (603351) has a Capital Reinvestment Ratio of 0.15x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥69.51 Million) in capital expenditures (CN¥10.29 Million). See net asset quality index of Nanjing Well Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Nanjing Well Pharmaceutical Co Ltd Capital Reinvestment Ratio (2014–2024)
This chart tracks Nanjing Well Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 10 annual periods. Check 603351 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Nanjing Well Pharmaceutical Co Ltd (2014–2024)
Year-by-year Capital Reinvestment Ratio for Nanjing Well Pharmaceutical Co Ltd from 2014 to 2024. For live market cap and broader valuation context, see Nanjing Well Pharmaceutical Co Ltd stock valuation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.23x | CN¥221.79 Million | CN¥51.46 Million | ▼ -61.8% |
| 2023 | 0.61x | CN¥120.24 Million | CN¥73.07 Million | ▼ -71.7% |
| 2022 | 2.15x | CN¥108.99 Million | CN¥233.90 Million | ▼ -29.1% |
| 2020 | 3.03x | CN¥93.30 Million | CN¥282.44 Million | ▲ +225.5% |
| 2019 | 0.93x | CN¥129.69 Million | CN¥120.62 Million | ▼ -22.9% |
| 2018 | 1.21x | CN¥63.76 Million | CN¥76.95 Million | ▲ +35.8% |
| 2017 | 0.89x | CN¥71.27 Million | CN¥63.35 Million | ▲ +64.4% |
| 2016 | 0.54x | CN¥128.18 Million | CN¥69.31 Million | ▼ -43.0% |
| 2015 | 0.95x | CN¥81.14 Million | CN¥76.92 Million | ▼ -20.1% |
| 2014 | 1.19x | CN¥74.62 Million | CN¥88.54 Million | — |